INCY vs PTHS · P/E 14, rev $5.14B vs rev $16.8M
Incyte Corporation (INCY) versus Pelthos Therapeutics Inc. (PTHS) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Pelthos Therapeutics Inc. (PTHS) is a biotechnology company listed on AMEX.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported PTHS revenue for 2025-12-31 was $16.8M. Net income was -$43.3M. PTHS currently screens at market cap $94.7M.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. PTHS currently screens at market cap $94.7M.
Not investment advice. Open the INCY and PTHS stock pages for the full models.
Not investment advice.